Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)

Background: Immune checkpoint inhibitor (ICI)-based combination therapy has transformed the therapeutic landscape of advanced hepatocellular carcinoma (aHCC). However, durable clinical benefit remains limited to a subset of patients, highlighting the need for approaches that enhance efficacy. Object...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Najib Ben Khaled, Ursula Ehmer, Ilja Kubisch, Maria A. Gonzalez-Carmona, Alexander Philipp, Max Seidensticker, Julia Altenhofer, Marion Basch, Tim Hüwer, Bettina Oehrle, Andreas Geier, Caterina Soldà, Alessandra Auriemma, Ulrike Bauer, Taotao Zhou, Lukas Perkhofer, Jack Chater, Arndt Weinmann, Johann von Felden, Antonio De Rosa, Caterina Vivaldi, Ignazio Piseddu, Isabel Schwald, Stefan Enssle, Monika Karin, Julia S. Schneider, Moritz N. Gröper, Katarina Ondrejkova, Lena Weiss, Georg Beyer, Kornelius Schulze, Lorenzo Antonuzzo, Gianluca Masi, Bruno Daniele, Jens Ricke, Julia Mayerle, Friedrich Foerster, Florian P. Reiter, Thomas J. Ettrich, Enrico N. De Toni
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	SAGE Publishing 2026-02-01
סדרה:	Therapeutic Advances in Medical Oncology
גישה מקוונת:	https://doi.org/10.1177/17588359261417640
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!